Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Ali Aminian
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
74High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07027969CT.gov Metabolic Surgery for Atrial Fibrillation Elimination | — | Not Yet Recruiting | — | — | — |
NCT07588750CT.gov Retrospective Evaluation of Sibutramine-Topiramate Therapy for Obesity in Real-World Outpatient Practice | — | Not Yet Recruiting | — | — | — |
NCT05209984CT.gov A Phase 3, Double-blind/Double-dummy, Safety/Efficacy/Superiority of Sibutramine/Topiramate XR in Adults With Overweight | — | Withdrawn | — | — | — |
NCT07213466CT.gov Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder | — | Recruiting | — | — | — |
NCT06854614CT.gov Sequential or CombinaTion Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial) | — | Active Not Recruiting | — | — | — |
NCT05975580CT.gov Pharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery | — | Recruiting | — | — | — |
NCT05756764CT.gov Anti-obesity Pharmacotherapy and Inflammation | — | Active Not Recruiting | — | — | — |
NCT04881799CT.gov Phentermine/Topiramate in Adolescents With Type 2 Diabetes and Obesity | — | Active Not Recruiting | — | — | — |
NCT04572217CT.gov Medications After Adolescent Bariatric Surgery | — | Withdrawn | — | — | — |
NCT04298203CT.gov Role of Pharmacotherapy in Counteracting Weight Regain in Adolescents With Severe Obesity | — | Completed | — | — | — |
Show 33 more trialsShow fewer
NCT04621929CT.gov Phentermine/Topiramate for Uric Acid Stones | — | Completed | — | — | — |
NCT04721873CT.gov Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese Patients | — | Recruiting | — | — | — |
NCT04531176CT.gov EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial | — | Terminated | — | — | — |
NCT04408586CT.gov Anti-Obesity Phentermine-Topiramate Extended Release Pharmacotherapy vs Placebo Among Patients Using a Wearable Activity Tracker | — | Completed | — | — | — |
NCT04007393CT.gov SMART Use of Medication for the Treatment of Adolescent Severe Obesity | — | Completed | — | — | — |
NCT03603080CT.gov Efficacy of Pharmacotherapy to Enhance Weight Loss Following Sleeve Gastrectomy | — | Terminated | — | — | — |
NCT03799198CT.gov Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity | — | Completed | — | — | — |
NCT03374956CT.gov Individualized Obesity Pharmacotherapy | — | Completed | — | — | — |
NCT02273804CT.gov Topiramate and Severe Obesity | — | Completed | — | — | — |
NCT02635386CT.gov EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS) | — | Completed | — | — | — |
NCT02301416CT.gov Qsymia as an Adjunct to Surgical Therapy in the Superobese | — | Completed | — | — | — |
NCT04453306CT.gov Treatment of Obesity With Topiramate in Patients With Polycystic Ovary Syndrome | — | Unknown | — | — | — |
NCT01859013CT.gov Topiramate in Adolescents With Severe Obesity | — | Completed | — | — | — |
NCT01834404CT.gov Peripheral Pharmacodynamics of Phentermine-Topiramate in Obese Patients | — | Completed | — | — | — |
NCT01384279CT.gov The Therapeutic Effects of Topiramate and Metformin on Second Generation Antipsychotics-induced Obesity | — | Completed | — | — | — |
NCT01351753CT.gov Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity | — | Terminated | — | — | — |
NCT00842400CT.gov A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects. | — | Completed | — | — | — |
NCT00563368CT.gov A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults | — | Completed | — | — | — |
NCT00554216CT.gov Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults | — | Completed | — | — | — |
NCT00518466CT.gov Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults | — | Completed | — | — | — |
NCT00231647CT.gov A Study on Efficacy and Safety of Topiramate OROS Controlled-Release in Obese, Type 2 Diabetic Subjects Managed With Diet or Metformin | — | Completed | — | — | — |
NCT00210808CT.gov A Study of the Effectiveness and Safety of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity | — | Completed | — | — | — |
NCT00231621CT.gov A Study on Efficacy and Safety of Topiramate in Treatment of Obese Subjects With Dyslipidemia | — | Terminated | — | — | — |
NCT00231634CT.gov A Study of the Efficacy and Safety of Topiramate in Obese, Type 2 Diabetic Patients Inadequately Controlled on Sulfonylurea Therapy | — | Terminated | — | — | — |
NCT00236665CT.gov A Study of Efficacy and Safety of Topiramate in the Treatment of Obese Patients With Mild to Moderate Essential Hypertension | — | Completed | — | — | — |
NCT00231530CT.gov A Study of the Safety and Efficacy of Topiramate in the Treatment of Obese, Type 2 Diabetes Patients on a Controlled Diet | — | Completed | — | — | — |
NCT00231660CT.gov A Study of the Efficacy and Safety of Topiramate in the Treatment fo Obese, Type 2 Diabetic Patients Treated With Metformin | — | Completed | — | — | — |
NCT00236613CT.gov A Study on Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity | — | Completed | — | — | — |
NCT02040311CT.gov Topiramate: Long-Term Maintenance of Weight Loss Induced by Low-Calorie Diet in Obese Subjects | — | Terminated | — | — | — |
NCT00236600CT.gov A Study on Efficacy and Safety of Topiramate in Maintaining Weight Loss in Obese Patients Following an Intensive, Non-Pharmacologic Weight Loss Program | — | Completed | — | — | — |
NCT00236639CT.gov A Study on Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity | — | Completed | — | — | — |
NCT00236626CT.gov A Study of the Safety and Effectiveness of Topiramate on Insulin Sensitivity in Overweight or Obese Patients With Type 2 Diabetes | — | Completed | — | — | — |
NCT00231608CT.gov A Study of Safety and Efficacy of Topiramate in Male Patients With Abdominal Obesity | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Obesity Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Topiramate (this asset) | Ali Aminian | Approved | BB · 68 |
| vi-0521 | VIVUS LLC | P4 | BBB |
| Tirzepatide | Royal North Shore Hospital | P4 | BBB |
| asc30 | Ascletis Pharma (China) Co., Limited | P2 | BBB |
| Phentermine | Russell McCulloh, MD | P4 | BBB |
| Survodutide | Boehringer Ingelheim | P3 | BBB |
| Deoxycholic Acid | University of California, San Diego | P4 | BBB |
| Efsubaglutide Alfa | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | P4 | BBB |
| Cagrilintide | Novo Nordisk A/S | P3 | BBB |
+42 more in the Obesity Disorder cohort
Other indications for Topiramate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Focal Epilepsy | — | P4 | A · 80 |
| Migraine Without Aura | — | P4 | BBB · 78 |
| Migraine With Aura | — | P4 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Topiramate in Obesity Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/topiramate-obesity-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →